SAN DIEGO--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the ...

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...

VANCOUVER, British Columbia — While eye pain outcomes were similar within a week of injection of either aflibercept or ranibizumab in patients with diabetic macular edema, more anterior chamber ...

A recent study found that the ranibizumab port delivery system (PDS) has cost-saving potential compared with regular ranibizumab or aflibercept injections for age-related macular degeneration if used ...

Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating ...

Please provide your email address to receive an email when new articles are posted on . Data from the ZIPANGU study showed the use of focal/grid short-pulse laser therapy in patients receiving ...

A dexamethasone implant significantly outperformed ranibizumab (Lucentis) and methotrexate for intravitreal treatment of persistent/recurrent uveitic macular edema, according to results of a ...

Basel, May 31, 2013 - Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis ® (ranibizumab) to treat patients with visual impairment due ...

The US Food and Drug Administration (FDA) has approved the first biosimilar for ophthalmology, Byooviz (ranibizumab-nuna), which will be indicated for neovascular (wet) age-related macular ...

Port Delivery System with ranibizumab (PDS) is a permanent refillable eye implant that continuously delivers ranibizumab over a period of months, potentially reducing the treatment burden associated ...